Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 257

recruiting
3 987
countries
28
conditions
2 109

4 491 trials match your criteria

Ischaemic stroke

Not recruiting

Study on Blood Pressure Management with Urapidil, Phenylephrine, and Labetalol for Patients with Acute Ischemic Stroke After Endovascular Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Urapidil

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate

Study of Ivosidenib and Azacitidine for Patients Aged 18 and Older with Untreated Acute Myeloid Leukemia with IDH1 Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Neoplasm

Not recruiting

Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Dermatomyositis

Not recruiting

Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin

Neuroblastoma

Not recruiting

Study on Bevacizumab with Temozolomide and Irinotecan for Children with Relapsed or Refractory Neuroblastoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Bevacizumab

Lung transplant+1

Not recruiting

Study on the Safety of Allogeneic Mesenchymal Stromal Cells for Patients with Chronic Lung Transplant Rejection

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danazol

Study on the Effects of Spironolactone, Pioglitazone, and Metformin for Adolescent Girls and Young Women with Polycystic Ovary Syndrome (PCOS)

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Metformin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.